BioCardia, Inc.
BCDA- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0000925741
In the last 90 days, BioCardia, Inc. insiders filed 10 open-market purchases and 0 sales; 21 institutions reported holding it in 13F filings for Q2 2026, worth $1.65M in total; no superinvestor holds it.
Q2 2021 vs. Q1 2021
How the institutions holding BioCardia, Inc. changed between Q1 2021 and Q2 2021.
All holders in Q2 2021All holders in Q1 2021
| Measure | Q1 2021 | Q2 2021 | Change |
|---|---|---|---|
| Holders | 19 | 20 | +1 |
| Shares | 3.12M | 3.10M | −20.7K (−0.7%) |
| Value | $13.5M | $12.3M | −$1.24M (−9.1%) |
New holders (4)
Institutions that held BioCardia, Inc. at the end of Q2 2021 but not at the end of Q1 2021.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| BlackRock Inc. | 35,927 | $143.0K | 0.00% |
| Virtu Financial LLC | 33,264 | $132.0K | 0.01% |
| Magnus Financial Group LLC | 15,000 | $60.0K | 0.01% |
| UBS Group AG | 3,750 | $15.0K | 0.00% |
Sold out (3)
Institutions that held BioCardia, Inc. at the end of Q1 2021 and filed for Q2 2021 without it.
| Institution | Shares, Q1 2021 | Value, Q1 2021 |
|---|---|---|
| Squarepoint Ops LLC | 46,945 | $204.0K |
| Engineers Gate Manager LP | 21,855 | $95.0K |
| Tower Research Capital LLC (TRC) | 3,194 | $14.0K |